VEGFR2/KDR/Flk-1 Antibody (91202) [Unconjugated]

Recombinant Mouse VEGFR2/KDR/Flk‑1 Fc Chimera (Catalog # 443-KD) inhibits Recombinant Mouse VEGF164 (Catalog # 493-MV) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse VEGF164 (5 ng/mL) activity elicited by Recombinant Mouse VEGFR2/KDR/Flk‑1 Fc Chimera (150 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGFR2/KDR/Flk‑1 Monoclonal Antibody (Catalog # MAB4431). The ND50 is typically 0.05-0.15 µg/mL.

• Reactivity: Mu
• Applications: B/N, ELISA(Cap)
• Clone: 91202
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

VEGFR2/KDR/Flk-1 Antibody (91202) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2
  Ala20-Glu762
  Accession # P35918
• Specificity: Detects mouse VEGFR2 in Western blots.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: KDR
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 0.05-0.15 ug/mL
• Application Notes: ELISA Detection: Mouse VEGF R2/KDR/Flk-1 Biotinylated Antibody (Catalog number BAF644)
  Standard: Recombinant Mouse VEGF R2/KDR/Flk-1 Fc Chimera (Catalog number 443-KD)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR2/KDR/Flk-1 Antibody (91202) [Unconjugated]

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) precursor protein with a 19 aa signal peptide. Mature VEGFR2 is composed of a 743 aa extracellular domain, a 22 aa transmembrane domain, and a 583 aa cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA 95:548.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR2/KDR/Flk-1 Antibody (MAB4431)(6)

Publications using MAB4431

• FA Rossato, Y Su, A Mackey, YSE Ng Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization Cells, 2020-09-09;9(9):. 2020-09-09 [PMID: 32917003] (Neutralization, Mouse)
• Jie Shi Chua, Vy M. Tran, Mausam Kalita, Maritza V. Quintero, Orlando Antelope, Geethu Muruganandam et al. A glycan-based approach to therapeutic angiogenesis PLOS ONE 8/1/2017 [PMID: 28763512]
• Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination Sci Rep, 2016-09-12;6(0):33162. 2016-09-12 [PMID: 27616470] (Neutralization, Mouse)
• Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med, 2015-01-19;212(2):139-48. 2015-01-19 [PMID: 25601652] (Neutralization, Mouse)
• Nagai , Norihiro, Lundh von Leithner , Pete, Izumi-Nagai , Kanako, Hosking , Brett, Chang , Bo, Hurd , Ron, Adamson , Peter, Adamis , Anthony, Foxton , Richard, Ng , Yin Shan, Shima , David T Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. Invest Ophthalmol Vis Sci, 2014-05-20;55(6):3709-19. 2014-05-20 [PMID: 24845632] (Neutralization, Mouse)
• Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood, 2007-11-27;111(4):1980-8. 2007-11-27 [PMID: 18042800] (ICC, IHC-Fr, Neutralization, Western Blot, Mouse)

Bioinformatics

• Gene Symbol: KDR
• Uniprot:
  • P35918()